Campath in Leukemia Yields to Lemtrada in Multiple Sclerosis
Sanofi SA is withdrawing the leukemia drug Campath (alemtuzumab), a major bone of contention during the fractious negotiations preceding its 2011 acquisition of Genzyme Corp., in favor of rebranding the CD52-targeting antibody as Lemtrada in the planned indication of multiple sclerosis (MS).
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST